N-piperidine Ibrutinib hydrochloride |
Catalog No.GC62255 |
N-피페리딘 이브루티닙 염산염(화합물 1)은 가역적인 이브루티닙 유도체입니다. N-피페리딘 이브루티닙 염산염은 WT BTK 및 C481S BTK에 대해 IC50이 각각 51.0 및 30.7nM인 강력한 BTK 억제제입니다. N-피페리딘 이브루티닙 염산염은 SJF620과 같은 일련의 PROTAC 합성에서 BTK 리간드로 사용할 수 있습니다. SJF620은 DC50이 7.9nM인 강력한 PROTAC BTK 분해제입니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2231747-18-3
Sample solution is provided at 25 µL, 10mM.
N-piperidine Ibrutinib hydrochloride (Compound 1) is a reversible Ibrutinib derivative. N-piperidine Ibrutinib hydrochloride is a potent BTK inhibitor with IC50s of 51.0 and 30.7 nM for WT BTK and C481S BTK, respectively[1]. N-piperidine Ibrutinib hydrochloride can be used as a BTK ligand in the synthesis of a series of PROTACs, such as SJF620 . SJF620 is a potent PROTAC BTK degrader with a DC50 of 7.9 nM[2].
N-piperidine Ibrutinib hydrochloride can be used as a BTK ligand in the synthesis of a series of PROTACs. SJF638, SJF678, and SJF608 are potent PROTAC BTK degraders with DC50s of 374, 162, and 8.3 nM, respectively[2].
[1]. Buhimschi AD, et al. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation. Biochemistry. 2018 Jul 3;57(26):3564-3575. [2]. Jaime-Figueroa S, et al. Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties. Bioorg Med Chem Lett. 2020 Feb 1;30(3):126877.
Average Rating: 5
(Based on Reviews and 14 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *